...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another IPO that shocks!

....patience....

When it was just the prostate study I thought there was a possibility of a buyout.  Then came the breast cancer study and I thought we'd have to wait another 3 years.  Now we're starting new studies over the next several months.  My current expectation is that we'll have to wait at least 3 more years before we see any $$$ in our pockets.

 

Share
New Message
Please login to post a reply